# EDGAR Filing Document

**Accession Number:** 0001552189
**File Stem:** 0001493152-23-004634
**Filing Date:** 2023-2
**Character Count:** 5360
**Document Hash:** 5b0321c3f6213c73793f8525dc557ca7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-004634.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001493152-23-004634

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230214

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PANACEA LIFE SCIENCES HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001552189
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 271085858
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38190
- **FILM NUMBER:** 23623164

**BUSINESS ADDRESS:**
- **STREET 1:** 5910 SOUTH UNIVERSITY BLVD
- **STREET 2:** C18-193
- **CITY:** GREENWOOD VILLAGE
- **STATE:** CO
- **ZIP:** 80121
- **BUSINESS PHONE:** 561-455-4822

**MAIL ADDRESS:**
- **STREET 1:** 5910 SOUTH UNIVERSITY BLVD
- **STREET 2:** C18-193
- **CITY:** GREENWOOD VILLAGE
- **STATE:** CO
- **ZIP:** 80121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Exactus, Inc.
- **DATE OF NAME CHANGE:** 20160328

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Spiral Energy Tech., Inc.
- **DATE OF NAME CHANGE:** 20131004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Solid Solar Energy, Inc.
- **DATE OF NAME CHANGE:** 20120613

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 14, 2023

**<u>PANACEA LIFE SCIENCES HOLDINGS, INC.</u>**

(Exact name of the registrant as specified in its charter)

<u>Nevada</u> <u>001-38190</u> <u>27-1085858</u> <br> (State or other jurisdiction of (Commission (IRS Employer <br> of incorporation) File Number) Identification No.)

5910 South University Blvd, C18-193

Greenwood Village, CO 80121

_____________________________________________

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: 1-800-985-0515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of exchange on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the "Company") entered into a Share Exchange Agreement with an institutional investor (the "Investor") pursuant to which the Investor exchanged 350 shares of the Company's Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the "Note").

The parties have agreed that the Company will repay the Note in full pursuant to the terms of a Note Payoff Agreement dated February 9, 2023, under which the Company shall pay to Investor (i) $135,000 on February 13, 2023; (ii) $100,000 on or before June 30, 2023, and (iii) shall convert 540,000 shares of the Company's Common Stock at a fixed conversion price of $0.25 per share.

The payment made on February 13, 2023 was funded under the Company's line of credit with its Chief Executive Officer.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Panacea Life Sciences Holdings, Inc. | Panacea Life Sciences Holdings, Inc. |
| Date: February 14, 2023 | By: | */s/ Leslie Buttorff* |
|  | Name: | Leslie Buttorff |
|  | Title: | Chief Executive Officer |

---